Xiaoguang Li
- Hepatology top 5%
- Hepatitis C virus research 6
- Modeling and Simulation top 10%
- Infectious Diseases top 10%
- SARS-CoV-2 and COVID-19 Research 4
- Pharmaceutical Science top 10%
-
- Liver Disease Diagnosis and Treatment 7
- Hepatitis B Virus Studies 6
- Respiratory viral infections research 5
- Influenza Virus Research Studies 3
-
- Metabolomics and Mass Spectrometry Studies 4
-
- Hormonal and reproductive studies 3
- Co-authors
- Gottfried KellermannMaosheng YaoZhenqiang XuQi ChenFangxia ShenYan WuShu LiJie Xu
- Journals
- SHILAP Revista de lepidopterología (4 papers)Nano Letters (1 paper)PLoS ONE (1 paper)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Xiaoguang Li
47 papers receiving 795 citations
Peers
Comparison fields: 5 of 122
- Hepatology 133
- Modeling and Simulation 34
- Infectious Diseases 126
- Pharmaceutical Science 39
- Epidemiology 194
Countries citing papers authored by Xiaoguang Li
This map shows the geographic impact of Xiaoguang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoguang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoguang Li more than expected).
Fields of papers citing papers by Xiaoguang Li
This network shows the impact of papers produced by Xiaoguang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoguang Li. The network helps show where Xiaoguang Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xiaoguang Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 4 | |
| 6 | 2021 | 24 | |
| 7 | 2020 | 8 | |
| 8 | 2019 | 17 | |
| 9 | 2018 | 8 | |
| 10 | 2017 | 22 | |
| 11 | 2017 | 44 | |
| 12 | 2017 | 5 | |
| 13 | 2016 | 29 | |
| 14 | 2015 | 2 | |
| 15 | 2015 | 30 | |
| 16 | 2015 | 19 | |
| 17 | 2014 | 1 | |
| 18 | 2012 | 51 | |
| 19 | [Fecal calprotectin in differential diagnosis of irritable bowel syndrome]. | 2006 | 9 |
| 20 | 2006 | 22 |
About Xiaoguang Li
Xiaoguang Li is a scholar working on Hepatology, Geriatrics and Gerontology and Modeling and Simulation, having authored 50 papers that have together received 829 indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (7 papers), Hepatitis B Virus Studies (6 papers), Hepatitis C virus research (6 papers), Respiratory viral infections research (5 papers), Metabolomics and Mass Spectrometry Studies (4 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Influenza Virus Research Studies (3 papers) and Hormonal and reproductive studies (3 papers). The work is most often cited by research in Hepatology (133 citations), Modeling and Simulation (34 citations) and Infectious Diseases (126 citations). Xiaoguang Li has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Gottfried Kellermann, Maosheng Yao, Zhenqiang Xu, Qi Chen, Fangxia Shen, Yan Wu, Shu Li, Shu Li, Jie Xu and Jie Xu. Their work appears in journals such as SHILAP Revista de lepidopterología, Nano Letters and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.